![Page 1: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/1.jpg)
Clinical Conference
Dana Assis, MD Tuesday March 22, 2016
![Page 2: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/2.jpg)
Case 70 yo male first presented to Bellevue 2009 – no hx of routine medical care previously. Diagnosed with HTN and DM. Followed for one year then lost in 2010. In 2012 diagnosis of clear cell renal cancer diagnosed in at Mt. Sinai. Had left kidney resection. Returns to Bellevue 2015 with diagnosis of SCC neck in setting of b/l PE. On workup also found to have pulmonary metastatic disease with pleural effusion consistent with metastatic RCC. Plan at that time from oncology sunitinib/pazopanib
![Page 3: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/3.jpg)
Renal cell carcinoma
• Disease incidence • Majority of cases occur sporadically • Pathology: Clear cell, papillary • 1/3 patients undergo nephrectomy will have
recurrence • Focus on treatment of advanced/metastatic
RCC
![Page 4: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/4.jpg)
Therapy for advanced renal cell carcinoma • Before 2005
• IL-2 • After 2005
• VEGF-pathway inhibitors • First line setting: sunitinib, pazopanib, bevacizumab (target VEGF)
• Median disease free survival 8-11 months • After progression w/first line: Sorafenib, axitinib
• Overall improvement in progression free survival (3-5 months) but not in overall survival
• mTOR inhibitors • Everolimus:
• Median progression free survival approx 5 months • overall survival approx 15mo no benefit when compared to placebo
![Page 5: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/5.jpg)
Molecular Pathways
HIF Hypoxia Inducible Factor VHL von Hippel-Lindau HGF Hepatocyte growth factor
![Page 6: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/6.jpg)
Newer agents
• Nivolumab • Inhibits T cell checkpoint regulator programmed death 1
(PD-1) • Monoclonal Ab to PD-1
• Cabozantinib • Multi kinase inhibitor targeting VEGFR, MET, RET, AXL • Oral small molecule inhibitor TK • Use medullary thyroid cancer
![Page 7: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/7.jpg)
![Page 8: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/8.jpg)
• PD-L1 expression associated with poor prognosis in RCC
• Over expression of PD-L1 inhibits activity of CD8 cells
• Iwai et al: Mouse model PD-1 deficient mice -myeloma suppressed
• Hematogenous spread of melanoma cells was inhibited in PD-1 deficient mice
Int. Immunol. (2005) 17 (2): 133-144.
![Page 9: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/9.jpg)
PD-1
![Page 10: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/10.jpg)
![Page 11: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/11.jpg)
![Page 12: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/12.jpg)
• Nivolumab • Total patients 821 Open Label RCT • Primary end point overall survival • Secondary end points
– Objective response rate – Progression free survival – Association overall survival and tumor expression
PD-L1 – Adverse events
![Page 13: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/13.jpg)
• Inclusion criteria – Dx advanced or metastatic disease – No more than 3 prev therapies – Disease progression – Karnofsky score 70
• Exclusion criteria – Mets CNS, prev rx mTOR inhibitor, required
glucocorticoids
• Patient population – Age 62, 70% M, 80% W, baseline functional status
![Page 14: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/14.jpg)
![Page 15: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/15.jpg)
Primary endpoint
Results • Median overall survival Nivolumab 25 months
compare to Everolimus 19.6 months • HR death 0.73 (CI 0.57 to 0.93) • Death in 183 patients of 410 Nivolumab • Death in 215 patients of 411 Everolimus
![Page 16: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/16.jpg)
![Page 17: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/17.jpg)
Secondary endpoints
• Partial response – 24% or 99 patients in Nivolumab – 5% or 20 patients in Everolimus
• Complete response – 1% or 4 patients in Nivolumab – <1% or 2 patients Everolimus
![Page 18: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/18.jpg)
![Page 19: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/19.jpg)
![Page 20: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/20.jpg)
Adverse Events • Everolimus group:
fatigue, stomatitis, anemia
• Nivolumab group: fatigue, nausea, pruritus
• Grade 3 or 4 event – 19% v 37%
![Page 21: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/21.jpg)
![Page 22: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/22.jpg)
Nivolumab group 21.8 months Everolimus group 18.8 months HR 0.79 CI 0.53 to 1.17
![Page 23: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/23.jpg)
Nivolumab group 27.4 months Everolimus group 21.1 months HR 0.77 CI 0.6 to 0.97
![Page 24: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/24.jpg)
Summary • Overall survival was longer • Fewer grade 3 or 4 adverse events
![Page 25: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/25.jpg)
![Page 26: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/26.jpg)
http://canceres.info/?farmaco=cabozantinib
![Page 27: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/27.jpg)
• Primary endpoint progression free survival • Open label Phase 3 trial • Included 658 patients
– Only 375 patients required to achieve primary end point
• Patient population – Age 60s, White, Male
![Page 28: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/28.jpg)
• Inclusion – Advanced/metastatic ccRCC – Prior treatment VEGFR, progression of disease – Brain mets ok if stable – No limit to previous anticancer therapy – Karnofsky score 70
• Exclusion – Therapy mTOR or cabozantinib – Uncontrolled clinically significant illness
![Page 29: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/29.jpg)
Results • Median progression free survival
– Cabozantinib 7.4 months vs 3.8 months Everolimus
– HR 0.58 CI 0.45 to 0.75 P<0.001
• Objective tumor response – 21% Cabozantinib v 5% Everolimus (P <0.001)
• Overall survival – trend toward longer survival with cabozantinib P value needed at interim analysis not reached
![Page 30: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/30.jpg)
![Page 31: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/31.jpg)
• Median follow up 7.6 and 4.4 months • Adverse events
– Grade 3 or 4 68% Cabozantinib (HTN, diarrhea, fatigue) and 58% with everolimus (anemia, fatigue, hyperglycemia)
![Page 32: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/32.jpg)
Summary • Progression free survival statistically
significant • Not powered for overall survival • Higher AE but equal in both groups
![Page 33: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/33.jpg)
Ongoing trials
• Atezolizumab in combination with Bevacizumab (or as monotherapy) versus Sunitinb in partipitants with untreated advanced RCC
• Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma
![Page 34: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/34.jpg)
![Page 35: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/35.jpg)
![Page 36: Clinical Conference - NYU Langone Health...carcinoma • Before 2005 • IL-2 ... • Use medullary thyroid cancer • PD-L1 expression associated with poor ... of PD-L1 inhibits activity](https://reader033.vdocument.in/reader033/viewer/2022051903/5ff41457655a7f6d506c24b8/html5/thumbnails/36.jpg)
Thank You